HOME > ARCHIVE
ARCHIVE
- BULLETIN
October 13, 2003
- REGULATORY NEWS IN BRIEF
October 13, 2003
- WORLD NEWS IN BRIEF
October 13, 2003
- Medical Members Submit Petition on Medical Fee Revision at Chuikyo
October 13, 2003
- To Ensure Bilateral Communication between Banyu, Merck: Mr Hirate
October 13, 2003
- Full Bungyo to Increase Medical Costs by \1.7 Tril.: Report
October 13, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 13, 2003
- Mr Butler Explains PhRMA Report on Value of New Medicines
October 13, 2003
- CORPORATE ROUNDUP NEWS IN BRIEF
October 13, 2003
- Sugi Yakkyoku: Strong Growth in 1st-half Sales, Profits
October 13, 2003
- PRESS SEMINAR
October 13, 2003
- Asahi Kasei Pharma Aims for Sales of \160 Bil. in FY2008
October 13, 2003
- NEW PRODUCTS
October 13, 2003
- Novartis Pharma Begins to Independently Market Zaditen
October 13, 2003
- Simvastatin Useful in Patients with Diabetic Complications
October 13, 2003
- Dainippon Aims to Boost MR Effectiveness via IT Solutions
October 13, 2003
- Fibrates Effective against Lipid Metabolism Disorders: Kaken
October 13, 2003
- MPC to Spin off Ethical Drug Manufacturing Division
October 13, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
October 13, 2003
- Sanwa Kagaku Kenkyusho: Glutest Neo Blood Glucose Meter
October 6, 2003
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
